No Data
Chengd Pharmaceutical (301201.SZ): Some fundraising projects have been completed.
On January 3, Gelonghui reported that Chengda Pharmaceutical Co., Ltd. (301201.SZ) announced that recently, the fundraising investment projects "Pharmaceutical Intermediate Project" and "Active Pharmaceutical Ingredient Project" have been completed and reached the designated usable status, meeting the project completion conditions. Therefore, the company has decided to conclude the "Pharmaceutical Intermediate Project" and "Active Pharmaceutical Ingredient Project."
Chengda Pharmaceutical (301201.SZ) has been re-certified as a high-tech enterprise.
On January 3, Gelonghui reported that Chengda Pharmaceutical (301201.SZ) recently received the "High-tech Enterprise Certificate" jointly issued by the Zhejiang Provincial Department of Economy and Information Technology, the Zhejiang Provincial Department of Finance, and the State Administration of Taxation Zhejiang Provincial Tax Service. The certificate number is GR202433007629, the issuance date is December 6, 2024, and the validity period is three years.
Chengda Pharmaceutical (301201.SZ): Active Pharmaceutical Ingredients such as Edaravone Sodium and Rivaroxaban are currently under registration application.
On December 17, Gelonghui reported that Chengda Pharmaceutical (301201.SZ) stated in a recent investor relations activity that the Active Pharmaceutical Ingredient L-carnitine has been approved by the regulatory authorities of several countries and obtained the CEP certification in Europe, covering quality system certification for major global markets. The Active Pharmaceutical Ingredient Brinfido has been approved by South Korea's MFDS, while the Active Pharmaceutical Ingredients Aflibercept and Rivaroxaban are in the process of registration. The Active Pharmaceutical Ingredient Daglizhuo passed CDE approval in November 2024, further enriching the company's product line.
Chengda Pharmaceutical (301201.SZ): The buyback has been completed, with a total of 2.10% of the company's shares repurchased.
On December 11, Gelianghui reported that Chengda Pharmaceutical (301201.SZ) announced that as of the date of this announcement, the company has repurchased a total of 3,244,700 shares through a special securities account for share repurchase via centralized bidding, accounting for 2.10% of the company's current total share capital (based on the current total share capital of 154,713,824 shares). The highest Fill Price was 22.21 yuan/share, the lowest Fill Price was 14.63 yuan/share, and the total amount of the repurchase was 57,061,614.15 yuan (excluding transaction fees), with the repurchase amount not lower than the lower limit of the total amount of the repurchase funds in the repurchase plan.
Chengda Pharmaceutical (301201.SZ): The L-carnitine series products are exported to over 30 global countries, with stable quality.
On December 9, Gelonghui reported that Chengda Pharmaceutical (301201.SZ) recently stated in an investor relations activity that the company's L-carnitine series products are exported to over 30 countries globally, with stable quality and a good international reputation, making it one of the main suppliers of L-carnitine worldwide. Currently, the sales prices of the company's L-carnitine products are relatively stable, having slightly improved from the lowest market prices, but there remains a certain level of uncertainty regarding the future price trend of related products.
November 22nd A-share investment lightning rod︱Changguang Huaxin: Shareholders Guotou Chuangye Ningbo Fund, Yili Suxin, and Nanjing Daofeng plan to collectively reduce their shareholding by no more than 2.01%.
*Shenzhen Coship Electronics: Termination of the application for reorganization and pre-reorganization to the court.
No Data
